MedTrace Logo

Therapeutic Effect of PBF-680 in Patients With COPD

NCT05262218 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2024-04-19

No results posted yet for this study

Summary

The purpose of the study is to investigate the effect of PBF-680 on the chronic inflammation and the lung function of patients with COPD on top of the standard medication. The effects of PBF-680 administration will also be examined with regards to symptom improvement and safety measures.One oral dose of PBF-680 or placebo will be administered daily for 4 weeks after randomization. The treatments will be administered double-blind with the Investigator and patient unaware of the treatment identity. A total of 102 COPD patients, either male or female, aged 40 to 80 years (inclusive) will be randomized.

Conditions

Interventions

DRUG

PBF-680 10mg

PBF-680 10mg administered orally once a day

DRUG

Placebo

Placebo administered orally once a day

Sponsors & Collaborators

  • Scope International AG

    collaborator INDUSTRY

  • Palobiofarma SL

    lead INDUSTRY

Principal Investigators

  • Nahomi Castro Palomino, PhD · Palobiofarma S.L

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-20
Primary Completion
2024-02-27
Completion
2024-04-09

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05262218 on ClinicalTrials.gov